Abstract: The invention provides novel, substituted 3-arylamino pyridine compounds pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.

Abstract: The invention provides novel, substituted 3-arylamino pyridine compounds pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.

Abstract: The invention provides novel, substituted 3-arylamino pyridine compounds pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.

Abstract: The invention provides novel, substituted 3-arylamino pyridine compounds pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.

Abstract: The present invention relates to substituted imidazopyridine derivatives as melanocortin-4 receptor (MC-4R) modulators, in particular as melanocortin-4 receptor antagonists. The antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, amytrophic lateral sclerosis (ALS), anxiety and depression.

Abstract: The invention provides novel, substituted 3-arylamino pyridine compounds pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.

Abstract: The invention provides novel, substituted 3-arylamino pyridine compounds pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.

Abstract: The invention provides novel, substituted 3-arylamino pyridine compounds (I) pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.

Abstract: The present invention relates to substituted phenylpiperidine derivatives as melanocortin-4 receptor modulators. Depending on the structure and the stereochemistry the compounds of the invention are either selective agonists or selective antagonists of the human melanocortin-4 receptor (MC-4R). The agonists can be used for the treatment of disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, anxiety and depression. Generally all diseases and disorders where the regulation of the MC-4R is involved can be treated with the compounds of the invention.

Abstract: The present invention relates to substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators. Depending on the structure and the stereochemistry the compounds of the invention are either selective agonists or selective antagonists of the human melanocortin-4 receptor (MC-4R). The agonists can be used for the treatment of disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, amyotrophic lateral sclerosis (ALS), anxiety and depression. Generally all diseases and disorders where the regulation of the MC-4R is involved can be treated with the compounds of the invention.

Abstract: The present invention relates to substituted imidazopyridine derivatives as melanocortin-4 receptor (MC-4R) modulators, in particular as melanocortin-4 receptor antagonists. The antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, amytrophic lateral sclerosis (ALS), anxiety and depression.

Abstract: The invention provides novel, substituted 3-arylamino pyridine compounds (I) pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.

Abstract: The invention provides novel, substituted 7-arylamino[1,2,4]triazolo[4,3-a]pyridine compounds Formula (I): pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10 R11, R12, R13, R14 and L are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.

Abstract: The invention provides novel, substituted 4-arylamino pyridone compounds (formula (I)), pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R 1, R2, R9, R 10, R 11, R 12, R 13, R 14 and L are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.

Abstract: Microwells, which are open on both sides and are arranged two-dimensionally in a microwell matrix (4), are hermetically closed by pressure on both sides using plugs (6) covered with a sealing sheet (11). A layer of elastic material (9), which is arranged between the plug (6) and the sealing sheet (11), guarantees uniform pressure on all the microwells of a microwell matrix (4) which is loosely held by a frame structure (1). Continuous peripheral elevations (2), which protrude in both directions at right angles to the plane of the microwell matrix (4), ensure that the deformable thin layer of elastic material (9) does not escape sideways between the plug (6) and the microwell matrix (4) during the pressing process. A plurality of microwell matrices (4) are held simultaneously by the frame structure (1) and are hermetically closed by a corresponding number of allocated plugs (6), which are fastened to a base plate (7) and a cover plate (8), respectively.

Abstract: The invention relates to microspheres with a narrow distribution of particle size and a uniform spherical shape, consisting of a partially or completely cross-linked polymer material. The invention also relates to a method for producing said microspheres and to the use thereof.

Abstract: A positioning device for glass microtiter plates (3) has a holding frame (1) with a support surface (2). Once introduced, the microtiter plate (3) is held in the position provided for it in the holding frame (1) by spring-like snap-in pins (5). Inwardly protruding projections (6) prevent the microtiter plate (3) from accidentally falling out of the holding frame (1). A continuous recess (7) in the area of the support surface (2) enables the microtiter plate (3) to be observed freely from both sides.

Abstract: Microwells, which are open on both sides and are arranged two-dimensionally in a microwell matrix (4), are hermetically closed by pressure on both sides using plugs (6) covered with a sealing sheet (11). A layer of elastic material (9), which is arranged between the plug (6) and the sealing sheet (11), guarantees uniform pressure on all the microwells of a microwell matrix (4) which is loosely held by a frame structure (1). Continuous peripheral elevations (2), which protrude in both directions at right angles to the plane of the microwell matrix (4), ensure that the deformable thin layer of elastic material (9) does not escape sideways between the plug (6) and the microwell matrix (4) during the pressing process. A plurality of microwell matrices (4) are held simultaneously by the frame structure (1) and are hermetically closed by a corresponding number of allocated plugs (6), which are fastened to a base plate (7) and a cover plate (8), respectively.

Abstract: When chemical substances are pipetted in individual microwells of a microwell array (4), problematic evaporation effects arise concerning the solvent with which the microwells are already filled. In order to prevent such undesired evaporation effects, a pipetting device for the automated pipetting of chemical substances having a holder (3), which receives at least one microwell array (4), and a pipetting head (11), which is fitted in such a way that it can be moved, is designed with the pipetting head (11) being fastened, by means of a holding device, to a plate (7) which follows the movements of the pipetting head (11) during the pipetting process. The plate (7) forms above the microwell array (4), in conjunction with a frame (5) tightly enclosing the microwell array (4), a sealed gas space (14) into which the pipetting head (11) protrudes through a matched hole (13) in the plate (7).

Abstract: The invention relates to an immunophilin ligand of Formula I and having antiasthmatic, antiallergic, antirheumatic, immunosuppressant, antipsoriatic and neuroprotectant properties,